DCGen is a genomic analysis technology company that offers a cutting-edge multigene assay kit called OncoFREE. This kit predicts prognosis for hormone receptor-positive, HER2-negative early-stage breast cancer patients by analyzing breast cancer tissue RNA expression data. DCGen also offers a test called HOPE that determines the risk for developing hereditary cancer. Their software tools assist with treatment and diagnosis, providing features for decision making, risk analysis, and surgery management.